 <h1>Topotecan Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2>In Summary</h2><p><b>Commonly reported side effects of topotecan include:</b> febrile neutropenia, sepsis, infection, abdominal pain, alopecia, anemia, asthenia, constipation, dyspnea, fatigue, fever, headache, leukopenia, nausea, neutropenia, stomatitis, thrombocytopenia, vomiting, granulocytopenia, diarrhea, and anorexia. <b>Other side effects include:</b> increased serum alanine aminotransferase, increased serum aspartate aminotransferase, intestinal obstruction, pain, and paresthesia.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to topotecan: oral capsule</i></p><p>Other dosage forms:</p><ul><li>intravenous powder for solution, intravenous solution</li></ul><h3>Warning</h3><p class="blackboxWarning-title">Oral route (Capsule)</p><p>Topotecan can cause severe myelosuppression. Administer first cycle only to patients with neutrophil counts greater than or equal to 1500/mm(3) and platelet counts greater than or equal to 100,000/mm(3). Monitor blood cell counts.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, topotecan may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking topotecan:</p><p>
<i>More common</i>
</p><ul>
<li>Black, tarry stools</li>
<li>bleeding gums</li>
<li>blood in the urine or stools</li>
<li>chest pain</li>
<li>chills</li>
<li>cough</li>
<li>fever</li>
<li>lower back or side pain</li>
<li>painful or difficult urination</li>
<li>pale skin</li>
<li>pinpoint red spots on the skin</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots on the lips or in the mouth</li>
<li>swollen glands</li>
<li>troubled breathing with exertion</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Cracked lips</li>
<li>diarrhea</li>
<li>difficulty in swallowing</li>
<li>dizziness</li>
<li>fast heartbeat</li>
<li>heartburn</li>
<li>hives, itching, skin rash</li>
<li>indigestion</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or genitals</li>
<li>nausea</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>severe abdominal pain, cramping, or burning</li>
<li>tightness in the chest</li>
<li>trouble breathing</li>
<li>vomiting of material that looks like coffee grounds, severe and continuing</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of topotecan may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Diarrhea</li>
<li>hair loss or thinning of the hair</li>
<li>lack or loss of strength</li>
<li>loss of appetite</li>
<li>vomiting</li>
<li>weight loss</li>
</ul><p>
<div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to topotecan: intravenous powder for injection, intravenous solution, oral capsule</i></p><h3>General</h3><p>The most common adverse events were hematologic: neutropenia, leukopenia, anemia, and thrombocytopenia.<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Neutropenia (up to 97%), leukopenia (97%), anemia (up to 94%), thrombocytopenia (up to 74%), pyrexia/grade 4 neutropenia (28%), febrile neutropenia (28%), hemorrhage (15%)</p>
<p><b>Common</b> (1% to 10%): Pancytopenia, coagulation adverse event</p>
<p><b>Postmarketing reports</b>: Severe bleeding (in association with thrombocytopenia)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (64%), other gastrointestinal adverse event (63%), vomiting (45%), diarrhea (32%), constipation (29%), abdominal pain (22%), stomatitis (18%)</p>
<p><b>Common</b> (1% to 10%): Abdominal pain, intestinal obstruction, dyspepsia</p>
<p><b>Frequency not reported</b>: Neutropenic colitis</p>
<p><b>Postmarketing reports</b>: Abdominal pain potentially associated with neutropenic colitis<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Rash includes pruritus, rash erythematous, urticaria, dermatitis, bullous eruption, and maculopapular rash.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Alopecia (49%), dermatologic adverse reaction (48%), rash (16%)</p>
<p><b>Common</b> (1% to 10%): Pruritus</p>
<p><b>Frequency not reported</b>: Urticaria</p>
<p><b>Postmarketing reports</b>: Angioedema, severe dermatitis, severe pruritus<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Sepsis or pyrexia/infection with neutropenia (43%), infection-febrile neutropenia (28%), infection (27%)</p>
<p><b>Common</b> (1% to 10%): Pneumonia, allergy-immunology adverse event, pharyngitis, rhinitis, sepsis</p><h3>Other</h3><p>Pain includes abdominal pain or cramping, arthralgia, bone pain, chest pain (non-cardiac and non-pleuritic), dysmenorrhea, dyspareunia, earache, headache, hepatic pain, myalgia, neuropathic pain, pain due to radiation, pelvic pain, pleuritic pain, rectal or perirectal pain, tumor pain, body pain, back pain, and skeletal pain.</p>
<p>"Constitutional" is a composite term that includes fatigue (lethargy, malaise, asthenia), fever (in the absence of neutropenia), rigors, chills, sweating, and weight gain or loss.</p><p><b>Very common</b> (10% or more): Constitutional (69%), pain (up to 59%), fatigue (29%), pyrexia (28%), asthenia (25%), mucositis (14%)</p>
<p><b>Common</b> (1% to 10%): Treatment related death, malaise</p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Dyspnea (22%), pulmonary adverse event (17%), coughing (15%)</p>
<p><b>Common</b> (1% to 10%): Epistaxis, respiratory disorder</p>
<p><b>Rare</b> (less than 0.1%): Interstitial lung disease</p>
<p><b>Postmarketing reports</b>: Fatal interstitial lung disease<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Hepatic adverse event (24%)</p>
<p><b>Common</b> (1% to 10%): Transient elevations in hepatic enzymes, hyperbilirubinemia, elevated ALT, elevated AST<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Non-neuropathy neurologic adverse event (35%), headache (18%)</p>
<p><b>Common</b> (1% to 10%): Paresthesia, neuropathy, dizziness</p>
<p><b>Uncommon</b> (0.1% to 1%): Hypoesthesia, peripheral neuropathy, paresis<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Cardiovascular adverse event (25%)<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Metabolic-laboratory adverse event (39%), anorexia (19%)</p>
<p><b>Frequency not reported</b>: Dehydration</p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Musculoskeletal adverse event (14%)<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Hypersensitivity (including rash)</p>
<p><b>Postmarketing reports</b>: Allergic manifestations, anaphylactoid reactions<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Genitourinary adverse event (36%)</p>
<p><b>Common</b> (1% to 10%): Sexual reproduction function adverse event<sup>[Ref]</sup></p><h3>Local</h3><p><b>Rare</b> (less than 0.1%): Extravasation</p>
<p><b>Postmarketing reports</b>: Inadvertent extravasation</p><h3>Endocrine</h3><p><b>Common</b> (1% to 10%): Endocrine adverse event</p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Ocular-visual adverse event</p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Lilenbaum RC, Ratain MJ, Miller AA, Hargis JB, Hollis DR, Rosner GL, O'Brien SM, Brewster L, Green MR, Schilsky RL "Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study." J Clin Oncol 13 (1995): 2230-7</p><p id="ref_2">2. Sabiers JH, Berger NA, Berger SJ, Haaga JR, Hoppel CL, Willson JK "Phase I trial of topotecan administered as a 72-hr infusion (Meeting abstract)." Proc Annu Meet Am Assoc Cancer Res 34 (1993): a25411993</p><p id="ref_3">3. Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, Wernz J, Chachoua A, Raphael B, Vinci RZ, et al "Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen." J Clin Oncol 12 (1994): 553-9</p><p id="ref_4">4. Eckardt J, Burris H, Kuhn J, Smith S, Rodriguez G, Weiss G, Smith L, Shaffer D, Johnson R, Von Hoff D "PHASE I AND PHARMACOKINETIC TRIAL OF CONTINUOUS INFUSION TOPOTECAN IN PATIENTS WITH REFRACTORY SOLID TUMORS (MEETING ABSTRACT)." Proc Annu Meet Am Soc Clin Oncol 11 (1992): a3731992</p><p id="ref_5">5. Saltz L, Sirott M, Young C, et al. "Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor." J Natl Cancer Inst 85 (1993): 1499-507</p><p id="ref_6">6. Betcher DL, Burnham N "Topotecan." J Pediatr Oncol Nurs 9 (1992): 31-2</p><p id="ref_7">7. Kantarjian HM, Beran M, Ellis A, Zwelling L, O'Brien S, Cazenave L, Koller C, Rios MB, Plunkett W, Keating MJ, et al "Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia." Blood 81 (1993): 1146-51</p><p id="ref_8">8. "Product Information. Hycamtin (topotecan)." SmithKline Beecham, Philadelphia, PA. </p><p id="ref_9">9. van Warmerdam LJ, ten Bokkel Huinink WW, Rodenhuis S, Koier I, Davies BE, Rosing H, Maes RA, Beijnen JH "Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion." J Clin Oncol 13 (1995): 1768-76</p><p id="ref_10">10. Stewart CF, Baker SD, Heideman RL, Jones D, Crom WR, Pratt CB "Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity." J Clin Oncol 12 (1994): 1946-54</p><p id="ref_11">11. Wall J, Burris H, Rodriguez G, Brown T, Weiss G, Kuhn J, Brown J, Johnson R, Friedman C, Mann W, et al "PHASE I TRIAL OF TOPOTECAN (SK AND F 104864) IN PATIENTS WITH REFRACTORY SOLID TUMORS (MEETING ABSTRACT)." Proc Annu Meet Am Soc Clin Oncol 10 (1991): a2611991</p><p id="ref_12">12. Janik J, Miller L, Smith J, Kopp W, Alvord G, Gause B, Curti B, Urba WJ, Longo DL "Prechemotherapy granulocyte-macrophage colony stimulating factor (GM- CSF) prevents topotecan-induced neutropenia (Meeting abstract)." Proc Annu Meet Am Soc Clin Oncol 12 (1993): a15071993</p><p id="ref_13">13. Miller AA, Hargis JB, Lilenbaum RC, Fields SZ, Rosner GL, Schilsky RL "Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study." J Clin Oncol 12 (1994): 2743-50</p><p id="ref_14">14. Rowinsky EK, Grochow LB, Hendricks CB, Ettinger DS, Forastiere AA, Hurowitz LA, McGuire WP, Sartorius SE, Lubejko BG, Kaufmann SH, et al "Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor." J Clin Oncol 10 (1992): 647-56</p><p id="ref_15">15. O'Brien S, Kantarjian H, Ellis A, Zwelling L, Estey E, Keating M "Topotecan in chronic lymphocytic leukemia." Cancer 75 (1995): 1104-8</p><p id="ref_16">16. Pratt CB, Stewart C, Santana VM, Bowman L, Furman W, Ochs J, Marina N, Kuttesch JF, Heideman R, Sandlund JT, et al "Phase I study of topotecan for pediatric patients with malignant solid tumors." J Clin Oncol 12 (1994): 539-43</p><p id="ref_17">17. Haas NB, LaCreta FP, Walczak J, Hudes GR, Brennan J, Ozols RF, O'Dwyer PJ "PHASE I/PHARMACOKINETIC TRIAL OF TOPOTECAN ON A WEEKLY 24-HOUR INFUSION SCHEDULE (MEETING ABSTRACT)." Proc Annu Meet Am Assoc Cancer Res 33 (1992): a31281992</p><p id="ref_18">18. Rowinsky EK, Adjei A, Donehower RC, Gore SD, Jones RJ, Burke PJ, Cheng YC, Grochow LB, Kaufmann SH "Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia." J Clin Oncol 12 (1994): 2193-203</p><p id="ref_19">19. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_20">20. Edgerton CC,  Gilman M,  Roth BJ "Topotecan-induced bronchiolitis." South Med J 97 (2004): 699-701</p></div>
<div class="more-resources" id="moreResources">
<h2>More about topotecan</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: miscellaneous antineoplastics</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Topotecan &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
<li>Topotecan Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Hycamtin</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +3 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Ovarian Cancer</li>
<li>Cervical Cancer</li>
<li>Cancer</li>
<li>Small Cell Lung Cancer</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to topotecan: intravenous powder for injection, intravenous solution, oral capsule</i></p><h3>General</h3><p>The most common adverse events were hematologic: neutropenia, leukopenia, anemia, and thrombocytopenia.<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Neutropenia (up to 97%), leukopenia (97%), anemia (up to 94%), thrombocytopenia (up to 74%), pyrexia/grade 4 neutropenia (28%), febrile neutropenia (28%), hemorrhage (15%)</p><p><b>Common</b> (1% to 10%): Pancytopenia, coagulation adverse event</p><p><b>Postmarketing reports</b>: Severe bleeding (in association with thrombocytopenia)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (64%), other gastrointestinal adverse event (63%), vomiting (45%), diarrhea (32%), constipation (29%), abdominal pain (22%), stomatitis (18%)</p><p><b>Common</b> (1% to 10%): Abdominal pain, intestinal obstruction, dyspepsia</p><p><b>Frequency not reported</b>: Neutropenic colitis</p><p><b>Postmarketing reports</b>: Abdominal pain potentially associated with neutropenic colitis<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Rash includes pruritus, rash erythematous, urticaria, dermatitis, bullous eruption, and maculopapular rash.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Alopecia (49%), dermatologic adverse reaction (48%), rash (16%)</p><p><b>Common</b> (1% to 10%): Pruritus</p><p><b>Frequency not reported</b>: Urticaria</p><p><b>Postmarketing reports</b>: Angioedema, severe dermatitis, severe pruritus<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Sepsis or pyrexia/infection with neutropenia (43%), infection-febrile neutropenia (28%), infection (27%)</p><p><b>Common</b> (1% to 10%): Pneumonia, allergy-immunology adverse event, pharyngitis, rhinitis, sepsis</p><h3>Other</h3><p>Pain includes abdominal pain or cramping, arthralgia, bone pain, chest pain (non-cardiac and non-pleuritic), dysmenorrhea, dyspareunia, earache, headache, hepatic pain, myalgia, neuropathic pain, pain due to radiation, pelvic pain, pleuritic pain, rectal or perirectal pain, tumor pain, body pain, back pain, and skeletal pain.</p><p>"Constitutional" is a composite term that includes fatigue (lethargy, malaise, asthenia), fever (in the absence of neutropenia), rigors, chills, sweating, and weight gain or loss.</p><p><b>Very common</b> (10% or more): Constitutional (69%), pain (up to 59%), fatigue (29%), pyrexia (28%), asthenia (25%), mucositis (14%)</p><p><b>Common</b> (1% to 10%): Treatment related death, malaise</p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Dyspnea (22%), pulmonary adverse event (17%), coughing (15%)</p><p><b>Common</b> (1% to 10%): Epistaxis, respiratory disorder</p><p><b>Rare</b> (less than 0.1%): Interstitial lung disease</p><p><b>Postmarketing reports</b>: Fatal interstitial lung disease<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Hepatic adverse event (24%)</p><p><b>Common</b> (1% to 10%): Transient elevations in hepatic enzymes, hyperbilirubinemia, elevated ALT, elevated AST<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Non-neuropathy neurologic adverse event (35%), headache (18%)</p><p><b>Common</b> (1% to 10%): Paresthesia, neuropathy, dizziness</p><p><b>Uncommon</b> (0.1% to 1%): Hypoesthesia, peripheral neuropathy, paresis<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Cardiovascular adverse event (25%)<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Metabolic-laboratory adverse event (39%), anorexia (19%)</p><p><b>Frequency not reported</b>: Dehydration</p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Musculoskeletal adverse event (14%)<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Hypersensitivity (including rash)</p><p><b>Postmarketing reports</b>: Allergic manifestations, anaphylactoid reactions<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Genitourinary adverse event (36%)</p><p><b>Common</b> (1% to 10%): Sexual reproduction function adverse event<sup>[Ref]</sup></p><h3>Local</h3><p><b>Rare</b> (less than 0.1%): Extravasation</p><p><b>Postmarketing reports</b>: Inadvertent extravasation</p><h3>Endocrine</h3><p><b>Common</b> (1% to 10%): Endocrine adverse event</p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Ocular-visual adverse event</p><p id="ref_1">1. Lilenbaum RC, Ratain MJ, Miller AA, Hargis JB, Hollis DR, Rosner GL, O'Brien SM, Brewster L, Green MR, Schilsky RL "Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study." J Clin Oncol 13 (1995): 2230-7</p><p id="ref_2">2. Sabiers JH, Berger NA, Berger SJ, Haaga JR, Hoppel CL, Willson JK "Phase I trial of topotecan administered as a 72-hr infusion (Meeting abstract)." Proc Annu Meet Am Assoc Cancer Res 34 (1993): a25411993</p><p id="ref_3">3. Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, Wernz J, Chachoua A, Raphael B, Vinci RZ, et al "Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen." J Clin Oncol 12 (1994): 553-9</p><p id="ref_4">4. Eckardt J, Burris H, Kuhn J, Smith S, Rodriguez G, Weiss G, Smith L, Shaffer D, Johnson R, Von Hoff D "PHASE I AND PHARMACOKINETIC TRIAL OF CONTINUOUS INFUSION TOPOTECAN IN PATIENTS WITH REFRACTORY SOLID TUMORS (MEETING ABSTRACT)." Proc Annu Meet Am Soc Clin Oncol 11 (1992): a3731992</p><p id="ref_5">5. Saltz L, Sirott M, Young C, et al. "Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor." J Natl Cancer Inst 85 (1993): 1499-507</p><p id="ref_6">6. Betcher DL, Burnham N "Topotecan." J Pediatr Oncol Nurs 9 (1992): 31-2</p><p id="ref_7">7. Kantarjian HM, Beran M, Ellis A, Zwelling L, O'Brien S, Cazenave L, Koller C, Rios MB, Plunkett W, Keating MJ, et al "Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia." Blood 81 (1993): 1146-51</p><p id="ref_8">8. "Product Information. Hycamtin (topotecan)." SmithKline Beecham, Philadelphia, PA. </p><p id="ref_9">9. van Warmerdam LJ, ten Bokkel Huinink WW, Rodenhuis S, Koier I, Davies BE, Rosing H, Maes RA, Beijnen JH "Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion." J Clin Oncol 13 (1995): 1768-76</p><p id="ref_10">10. Stewart CF, Baker SD, Heideman RL, Jones D, Crom WR, Pratt CB "Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity." J Clin Oncol 12 (1994): 1946-54</p><p id="ref_11">11. Wall J, Burris H, Rodriguez G, Brown T, Weiss G, Kuhn J, Brown J, Johnson R, Friedman C, Mann W, et al "PHASE I TRIAL OF TOPOTECAN (SK AND F 104864) IN PATIENTS WITH REFRACTORY SOLID TUMORS (MEETING ABSTRACT)." Proc Annu Meet Am Soc Clin Oncol 10 (1991): a2611991</p><p id="ref_12">12. Janik J, Miller L, Smith J, Kopp W, Alvord G, Gause B, Curti B, Urba WJ, Longo DL "Prechemotherapy granulocyte-macrophage colony stimulating factor (GM- CSF) prevents topotecan-induced neutropenia (Meeting abstract)." Proc Annu Meet Am Soc Clin Oncol 12 (1993): a15071993</p><p id="ref_13">13. Miller AA, Hargis JB, Lilenbaum RC, Fields SZ, Rosner GL, Schilsky RL "Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study." J Clin Oncol 12 (1994): 2743-50</p><p id="ref_14">14. Rowinsky EK, Grochow LB, Hendricks CB, Ettinger DS, Forastiere AA, Hurowitz LA, McGuire WP, Sartorius SE, Lubejko BG, Kaufmann SH, et al "Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor." J Clin Oncol 10 (1992): 647-56</p><p id="ref_15">15. O'Brien S, Kantarjian H, Ellis A, Zwelling L, Estey E, Keating M "Topotecan in chronic lymphocytic leukemia." Cancer 75 (1995): 1104-8</p><p id="ref_16">16. Pratt CB, Stewart C, Santana VM, Bowman L, Furman W, Ochs J, Marina N, Kuttesch JF, Heideman R, Sandlund JT, et al "Phase I study of topotecan for pediatric patients with malignant solid tumors." J Clin Oncol 12 (1994): 539-43</p><p id="ref_17">17. Haas NB, LaCreta FP, Walczak J, Hudes GR, Brennan J, Ozols RF, O'Dwyer PJ "PHASE I/PHARMACOKINETIC TRIAL OF TOPOTECAN ON A WEEKLY 24-HOUR INFUSION SCHEDULE (MEETING ABSTRACT)." Proc Annu Meet Am Assoc Cancer Res 33 (1992): a31281992</p><p id="ref_18">18. Rowinsky EK, Adjei A, Donehower RC, Gore SD, Jones RJ, Burke PJ, Cheng YC, Grochow LB, Kaufmann SH "Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia." J Clin Oncol 12 (1994): 2193-203</p><p id="ref_19">19. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_20">20. Edgerton CC,  Gilman M,  Roth BJ "Topotecan-induced bronchiolitis." South Med J 97 (2004): 699-701</p><h2>More about topotecan</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: miscellaneous antineoplastics</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Topotecan &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
<li>Topotecan Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +3 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Ovarian Cancer</li>
<li>Cervical Cancer</li>
<li>Cancer</li>
<li>Small Cell Lung Cancer</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>